Insights

Innovative Therapies Call for an Integrated Drug Safety and Compliance Model

In this article, Herbert Lee, PharmD, Senior Vice President, Medical Communications and Pharmacovigilance, makes the case for an integrated approach to ensuring the safe and effective use of medications by patients. From emerging therapies to innovative…

Articles

Building a Service Offering from the Research Lab to the Patient’s Home

A Conversation with Pharmaceutical Commerce & Jim Lang, Chief Executive Officer, EVERSANA Not quite a year ago, an assemblage of pharma service providers came into being as EVERSANA. Funded by two private equity firms with a…

Are We Transforming In The Right Way?

Why Product Launches Can’t Be Distracted By Empty Promises. We can all agree that innovations in therapeutic development have advanced beyond traditional product launch strategies and service models. In every step of the product lifecycle, we…

Power in numbers: Seven national plans manage almost half of the medical lives in the U.S.

Market Access Macrotrends provides  insight for you to stay on top of market access trends, anticipate how the healthcare landscape is evolving, and provide strategic guidance for your organization. Market Access Macrotrends answers your questions about changes in…

A More Trusting Relationship Can Lead to a Better Patient Experience

In this September feature, PM360 dives into what it takes to create relationships and experiences with and for patients. Considering that patients want more authentic interactions when dealing with life sciences companies, Jenny Sparano, director of…

Driving the Commercialization of Regenerative Medicine

With more than 7,000 distinct types of rare and genetic diseases and 400+ million individuals suffering from a rare disease, regenerative medicine holds the hope for a cure – transforming healthcare by revolutionizing patient care from…

Technology + Compliance = Improved Models of Care in Life Science Services

Compliance is a broad and extremely important area in almost every industry and more so in life sciences as it directly and indirectly impacts patient lives. Because the life science industry is continuously evolving, we are…

Four Key Questions About Patient Experience in 2019

In this September feature, PM360 asked experts for insight into the changes that need to happen to create better experiences for patients and ultimately serve them better. Kathi Henson, Chief Patient Service Officer, shares insight into…

Best Strategies for Co-Creating Solutions with Patients

In the September Think Tank, PM360 asks patients and experts at agencies and life sciences companies to share their best co-creation solutions in developing successful patient-centric strategies. Nicole Pitaniello, Managing Director of Client Services at the…

Pushing Your Frontline Into A New Frontier

The pharmaceutical industry is complex. A litany of companies and brands are competing for top-of-mind usage with clinicians, a cohesive partnership with payers, and active engagement with patients. It’s hard enough to bring a drug to…

white paper-insights
340B Drug Pricing: Challenges and Best Practices

Enacted in 1992, the 340B Drug Pricing Program was intended to stretch scarce federal resources and services to more eligible patients. Despite achieving this goal in many respects, it has  also become notoriously difficult to manage…